Skip to content
DataLookout
Menu

ADOPT-lungNCT06284317

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 29 versions: 28 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 42 → 45 locations
  2. Notable Eligibility criteria expanded, about 35 words
    • Study sites: 42 to 44
    • Secondary endpoints: details revised at 6 of 6 entries
  3. Minor Site details revised at 1 of 42 sitesv27
  4. Minor Site details revised at 1 of 42 sitesv26
  5. Minor Site details revised at 1 of 42 sitesv25
Show 22 earlier versionsHide 22 earlier versions
  1. Minor Site details revised at 1 of 42 sitesv24
  2. Minor Site details revised at 1 of 42 sitesv23
  3. Minor Site details revised at 1 of 42 sitesv22
  4. Minor Site details revised at 2 of 42 sitesv21
  5. Minor Study sites revised (42)v20
  6. Minor Site details revised at 1 of 42 sitesv19
  7. Minor Site details revised at 2 of 42 sitesv17
  8. Minor Site details revised at 1 of 42 sitesv16
  9. Minor Site details revised at 1 of 42 sitesv15
  10. Minor Site details revised at 1 of 42 sitesv14
  11. Minor Site details revised at 2 of 42 sitesv13
  12. Minor Site details revised at 3 of 42 sitesv12
  13. Minor Site details revised at 1 of 42 sitesv11
  14. Minor Start date changed from estimate of Feb 2025 to Jan 15, 2025v10
  15. Minor Site details revised at 1 of 42 sitesv9
  16. Minor Site details revised at 1 of 42 sitesv8
  17. Minor Site details revised at 1 of 42 sitesv7
  18. Minor Site details revised at 2 of 42 sitesv6
  19. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 2024 to Feb 2025
    • Study sites: 0 to 42
    v5
  20. Notable Start date: Oct 2024 to Dec 2024
    • Secondary endpoints: 13 to 6
    v4
  21. Minor Primary completion date: Oct 1, 2029 to Oct 2029
    • Study completion date: Jan 1, 2030 to Mar 2030
    • Start date: Oct 1, 2024 to Oct 2024
    v3
  22. Minor Study title shortened, about 6 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Disease-free survival (DFS)
Timeframe: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Secondary (6)

DFS in patients with pCR
Overall survival (OS) in patients with/without pCR
DFS in patients with/without ctDNA clearance
Time to recurrence (TTR) in patients with/without pCR
Time to treatment discontinuation (TTD) in patients with/without pCR
Show 1 moreShow less
Toxicity according to CTCAE v5.0

Arms and interventions

DurvalumabExperimental

Protocol treatment in the adjuvant phase consists of adjuvant durvalumab

ObservationNo intervention

Observation only

Drugs: Adjuvant durvalumab

Sites

45 sites in 10 countries

Australia 10, Switzerland 9, United Kingdom 7, Italy 6, France 5, Belgium 2, Ireland 2, Netherlands 2, Austria 1, Estonia 1